Clareo Health | Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).
Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Milton S. Hershey Medical Center
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willingness and ability to sign and date the study-specific informed consent form.
Stated willingness to comply with all study procedures and attend all study visits to the best of his or her ability for the duration of the study.
Age greater than 18yo.
Stage I-III TNBC or stage IV TNBC with intact breast primary.
Planned combined ICI therapy as per SoC by treating oncologist.
You may not be if
Other clinical trials are not excluded but participation must be cleared with the other clinical trial PIs.
Patients not suitable to undergo contrast enhanced ultrasound (i.e., pregnant women, known allergy to eggs, or a past allergic reaction to sonographic contrast or its components, such as polyethylene glycol (PEG))
